3rd Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$105,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Korea US Free Trade Agreement

LobbyistCovered position, as disclosed
HEIDI L WAGNER —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Monitor implementation of PPACA, including provisions relating to orphan drugs and regulatory pathway for biosimilars. Monitor deficit reduction initatives, including Budget Control Act of 2011

LobbyistCovered position, as disclosed
HEIDI L WAGNER —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.